Literature DB >> 23817321

Epidemiology and natural history of HCV infection.

Behzad Hajarizadeh1, Jason Grebely, Gregory J Dore.   

Abstract

Worldwide, an estimated 130-170 million people have HCV infection. HCV prevalence is highest in Egypt at >10% of the general population and China has the most people with HCV (29.8 million). Differences in past HCV incidence and current HCV prevalence, together with the generally protracted nature of HCV disease progression, has led to considerable diversity in the burden of advanced liver disease in different countries. Countries with a high incidence of HCV or peak incidence in the recent past will have further escalations in HCV-related cirrhosis and hepatocellular carcinoma (HCC) over the next two decades. Acute HCV infection is difficult to detect because of the generally asymptomatic nature of the disease and the marginalization of at-risk populations. Around 25% of patients with acute HCV infection undergo spontaneous clearance, with increased rates among those with favourable IL28B genotypes, acute symptoms and in women. The remaining 75% of patients progress to chronic HCV infection and are subsequently at risk of progression to hepatic fibrosis, cirrhosis and HCC. Chronic hepatitis C generally progresses slowly in the initial two decades, but can be accelerated during this time as a result of advancing age and co-factors such as heavy alcohol intake and HIV co-infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23817321     DOI: 10.1038/nrgastro.2013.107

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  138 in total

Review 1.  Hepatitis C virus infection in USA: an estimate of true prevalence.

Authors:  Eric Chak; Andrew H Talal; Kenneth E Sherman; Eugene R Schiff; Sammy Saab
Journal:  Liver Int       Date:  2011-03-16       Impact factor: 5.828

2.  Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support.

Authors:  Jason Grebely; Elizabeth Knight; Krista A Genoway; Mark Viljoen; Milan Khara; Doug Elliott; Lesley Gallagher; Michelle Storms; Jesse D Raffa; Stanley DeVlaming; Fiona Duncan; Brian Conway
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-03       Impact factor: 2.566

3.  HCV burden of infection in Egypt: results from a nationwide survey.

Authors:  J Guerra; M Garenne; M K Mohamed; A Fontanet
Journal:  J Viral Hepat       Date:  2012-02-06       Impact factor: 3.728

4.  Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents.

Authors:  J Grebely; J D Raffa; C Lai; T Kerr; B Fischer; M Krajden; G J Dore; M W Tyndall
Journal:  J Viral Hepat       Date:  2011-01       Impact factor: 3.728

5.  Risk factors for hepatitis C virus infection among blood donors in northern Thailand.

Authors:  Lakkana Thaikruea; Satawat Thongsawat; Niwat Maneekarn; Dale Netski; David L Thomas; Kenrad E Nelson
Journal:  Transfusion       Date:  2004-10       Impact factor: 3.157

6.  Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus.

Authors:  Thomas P Giordano; Louise Henderson; Ola Landgren; Elizabeth Y Chiao; Jennifer R Kramer; Hashem El-Serag; Eric A Engels
Journal:  JAMA       Date:  2007-05-09       Impact factor: 56.272

7.  Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection.

Authors:  Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

8.  Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum.

Authors:  O Dalgard; S Jeansson; K Skaug; N Raknerud; H Bell
Journal:  Scand J Gastroenterol       Date:  2003-08       Impact factor: 2.423

9.  Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou-Charentes region.

Authors:  Gautier Defossez; Alain Verneau; Isabelle Ingrand; Christine Silvain; Pierre Ingrand; Michel Beauchant
Journal:  Eur J Gastroenterol Hepatol       Date:  2008-05       Impact factor: 2.566

10.  Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors.

Authors:  Christine Meffre; Yann Le Strat; Elisabeth Delarocque-Astagneau; Fréderic Dubois; Denise Antona; Jean-Marie Lemasson; Josiane Warszawski; Josiane Steinmetz; Dominique Coste; Jean-François Meyer; Sandrine Leiser; Jean-Pierre Giordanella; René Gueguen; Jean-Claude Desenclos
Journal:  J Med Virol       Date:  2010-04       Impact factor: 2.327

View more
  325 in total

Review 1.  How do persistent infections with hepatitis C virus cause liver cancer?

Authors:  Jonathan K Mitchell; Stanley M Lemon; David R McGivern
Journal:  Curr Opin Virol       Date:  2015-09-29       Impact factor: 7.090

Review 2.  Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.

Authors:  Juan-Ramón Larrubia; Elia Moreno-Cubero; Joaquín Miquel; Eduardo Sanz-de-Villalobos
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

3.  A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.

Authors:  Adam Zuiani; Kevin Chen; Megan C Schwarz; James P White; Vincent C Luca; Daved H Fremont; David Wang; Matthew J Evans; Michael S Diamond
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

4.  Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.

Authors:  J Grebely; A Litwin; G J Dore
Journal:  J Viral Hepat       Date:  2016-06-08       Impact factor: 3.728

5.  Retreatment with peginterferon and ribavirin in chronic hepatitis C.

Authors:  Yong Min Jo; Sung Wook Lee; Sang Young Han; Yang Hyun Baek; Soo Young Kim; Woo Jae Kim; Ji Hye Ahn; Ji Young Lee
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

6.  Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients.

Authors:  Kazuki Ohashi; Toru Ishikawa; Mitsuyuki Suzuki; Hiroko Abe; Fujiko Koyama; Tomomi Nakano; Aya Ueki; Hirohito Noguchi; Erina Hasegawa; Shiori Hirosawa; Miki Kobayashi; Hiroshi Hirosawa; Kaede Sato; Takako Fukazawa; Yuka Maruyama; Toshiaki Yoshida
Journal:  Exp Ther Med       Date:  2017-11-10       Impact factor: 2.447

7.  Acceptability of Patient-Reported Outcome and Experience Measures for Hepatitis C Treatment Among People Who Use Drugs.

Authors:  Annie Madden; Max Hopwood; Joanne Neale; Carla Treloar
Journal:  Patient       Date:  2019-04       Impact factor: 3.883

Review 8.  Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.

Authors:  Heidi Barth
Journal:  World J Hepatol       Date:  2015-04-18

9.  Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia.

Authors:  Chaturaka Rodrigo; Auda A Eltahla; Rowena A Bull; Jason Grebely; Gregory J Dore; Tanya Applegate; Kimberly Page; Julie Bruneau; Meghan D Morris; Andrea L Cox; William Osburn; Arthur Y Kim; Janke Schinkel; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Margaret Hellard; Maria Prins; Chris Estes; Homie Razavi; Andrew R Lloyd; Fabio Luciani
Journal:  J Infect Dis       Date:  2016-08-28       Impact factor: 5.226

10.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2015-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.